A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major

NCT07489196 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

β-thalassemia Major

Interventions

GENETIC: CS-101 injection

Sponsor

CorrectSequence Therapeutics Co., Ltd